3 results match your criteria: "d Royal National Hospital for Rheumatic Diseases[Affiliation]"
Biologics for treating axial spondyloarthritis.
Expert Opin Biol Ther
June 2018
e Centre for Rheumatology & MRC Centre for Neuromuscular Diseases , University College London, London , United Kingdom of Great Britain and Northern Ireland.
Introduction: Spondyloarthritis (SpA) encompasses a heterogeneous group of diseases sharing genetic, immunological, clinical and imaging features. Axial spondyloarthritis (axSpA) refers to a subgroup characterised predominately by inflammation of the axial skeleton with subsequent symptoms of chronic (often inflammatory) back pain and sacroiliitis. There is a strong association with the major histocompatibility complex (MHC) class I allele human leukocyte antigen (HLA) B27.
View Article and Find Full Text PDFMonitoring patients with ankylosing spondylitis on anti-TNF monotherapy: too much too often?
Scand J Rheumatol
July 2017
d Royal National Hospital for Rheumatic Diseases, NHS Foundation Trust , Bath , UK.
Anxiety at 13 and its effect on pain, pain-related anxiety, and pain-related disability at 17: An ALSPAC cohort longitudinal analysis.
Psychol Health Med
May 2017
a Centre for Pain Research , University of Bath, Bath , BA2 7AY , UK.
The aim of the present study was to investigate the influence of anxiety at 13 years of age on the presence of chronic pain, pain-related anxiety, and pain-related disability at 17 years of age in a large longitudinal cohort. We hypothesized that mother-reported anxiety at 13 would be associated with the presence of chronic pain at 17 and an increase in pain-related anxiety using all available data from the longitudinal cohort. Further, we hypothesized that anxiety at 13 would predict pain-related disability in adolescents who reported chronic pain at 17 years of age.
View Article and Find Full Text PDF